69 related articles for article (PubMed ID: 26585134)
41. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
42. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
43. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
Toko T; Shibata J; Nukatsuka M; Yamada Y
Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
[TBL] [Abstract][Full Text] [Related]
44. Novel fluorescence based receptor binding assay method for receptors lacking ligand conjugates with preserved affinity: study on estrogen receptor alpha.
Christoph S; Meyer-Almes FJ
Biopolymers; 2003; 72(4):256-63. PubMed ID: 12833480
[TBL] [Abstract][Full Text] [Related]
45. Cytofluorometric analysis for estrogen receptors using fluorescent estrogen probes.
Kute TE; Linville C; Barrows G
Cytometry; 1983 Sep; 4(2):132-40. PubMed ID: 6685018
[TBL] [Abstract][Full Text] [Related]
46. Improved specificity of hippocampal memory trace labeling.
Cazzulino AS; Martinez R; Tomm NK; Denny CA
Hippocampus; 2016 Jun; 26(6):752-62. PubMed ID: 26662713
[TBL] [Abstract][Full Text] [Related]
47. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding.
Pappas TC; Gametchu B; Watson CS
FASEB J; 1995 Mar; 9(5):404-10. PubMed ID: 7896011
[TBL] [Abstract][Full Text] [Related]
48. FRET mechanism between a fluorescent breast-cancer drug and photodynamic therapy sensitizers.
Lahoz F; Scholz LE; Boto A; Díaz M
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Oct; 239():118498. PubMed ID: 32470814
[TBL] [Abstract][Full Text] [Related]
49. 1,2-Diaryl-3,4-dihydronaphthalenes: photofluorogenic ligands for the estrogen receptor.
Bindal RD; Katzenellenbogen JA
J Steroid Biochem; 1985 Dec; 23(6A):929-37. PubMed ID: 4094420
[TBL] [Abstract][Full Text] [Related]
50. Synthesis of a novel fluorescent probe for estrogen receptor.
Adamczyk M; Reddy RE; Yu Z
Bioorg Med Chem Lett; 2002 May; 12(9):1283-5. PubMed ID: 11965371
[TBL] [Abstract][Full Text] [Related]
51. Facile synthesis of high affinity styrylpyridine systems as inherently fluorescent ligands for the estrogen receptor.
Meyers MJ; Carlson KE; Katzenellenbogen JA
Bioorg Med Chem Lett; 1998 Dec; 8(24):3589-94. PubMed ID: 9934476
[TBL] [Abstract][Full Text] [Related]
52. Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.
Fang Z; Corbizi Fattori G; McKerrell T; Boucher RH; Jackson A; Fletcher RS; Forte D; Martin JE; Fox S; Roberts J; Glover R; Harris E; Bridges HR; Grassi L; Rodriguez-Meira A; Mead AJ; Knapper S; Ewing J; Butt NM; Jain M; Francis S; Clark FJ; Coppell J; McMullin MF; Wadelin F; Narayanan S; Milojkovic D; Drummond MW; Sekhar M; ElDaly H; Hirst J; Paramor M; Baxter EJ; Godfrey AL; Harrison CN; Méndez-Ferrer S
Nat Commun; 2023 Nov; 14(1):7725. PubMed ID: 38001082
[TBL] [Abstract][Full Text] [Related]
53. Colocalization of Estrogen Receptors with the Fluorescent Tamoxifen Derivative, FLTX1, Analyzed by Confocal Microscopy.
Morales A; Marín R; Marrero-Alonso J; Boto A; Díaz M
Methods Mol Biol; 2016; 1366():163-173. PubMed ID: 26585134
[TBL] [Abstract][Full Text] [Related]
54. Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1.
Marrero-Alonso J; Morales A; García Marrero B; Boto A; Marín R; Cury D; Gómez T; Fernández-Pérez L; Lahoz F; Díaz M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):898-910. PubMed ID: 23727370
[TBL] [Abstract][Full Text] [Related]
55.
Díaz M; Lobo F; Hernández D; Amesty Á; Valdés-Baizabal C; Canerina-Amaro A; Mesa-Herrera F; Soler K; Boto A; Marín R; Estévez-Braun A; Lahoz F
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069498
[TBL] [Abstract][Full Text] [Related]
56. A new selective fluorescent probe based on tamoxifen.
Ho LA; Thomas E; McLaughlin RA; Flematti GR; Fuller RO
Bioorg Med Chem Lett; 2016 Oct; 26(20):4879-4883. PubMed ID: 27662800
[TBL] [Abstract][Full Text] [Related]
57. Antagonism to estradiol in the mouse: reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg2+-soluble chromatin fraction.
Pavlik EJ; van Nagell JR; Nelson K; Gallion H; Donaldson ES; Kenady DE; Baranowska-Kortylewicz J
Endocrinology; 1986 May; 118(5):1924-34. PubMed ID: 2422013
[TBL] [Abstract][Full Text] [Related]
58. Review of fluorescent steroidal ligands for the estrogen receptor 1995-2018.
Gajadeera N; Hanson RN
Steroids; 2019 Apr; 144():30-46. PubMed ID: 30738074
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
